Skip to main content
. 2016 Jan 25;7(8):9448–9461. doi: 10.18632/oncotarget.7021

Figure 4. Association between postoperative survivals and HCC patients carrying LFCDs with or without hepatic HBV polymerase antigen expression.

Figure 4

A. Southern blot analysis of precore/core PCR amplicons derived from liver tissues of HCC patients. The positions of PCR products containing wild type (Wt) and LFCD (Del) were marked to the right. P, 1 pg of PCR product from Wt precore/core sequence as positive control; N, 10 pg of non-HBV DNA as negative control; Solid triangles, patients with LFCD. B and C. Kaplan-Meier survival analysis for postoperative recurrence-free survival (B) and overall survival (C) between HCC patients with (+, green lines) and without (−, blue lines) LFCD. D and E. Comparison of postoperative recurrence-free survivals between patients with hepatic HBV polymerase antigen positive (+) and those with polymerase antigen negative (−) reaction by immunohistochemistry (D). Combined analysis of polymerase (+)/(−) and LFCD (+)/(−) status (E). Kaplan-Meier analysis was used.